UTHealth Houston partners with UTMB Health to lead Texas-funded ibogaine clinical trials under IMPACT consortium

Ibogaine clinical trials in Texas received a $50 million grant from the Texas Health and Human Services Commission to support a two-year, multicenter study led by UTHealth Houston with UTMB Health. The statewide partnership, IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma), will test ibogaine in patients with addiction, traumatic brain injury, and related behavioral health conditions. UTHealth Houston and partners focus on addiction and associated conditions, while UT Austin and Baylor College of Medicine concentrate on traumatic brain injury, especially among veterans. A consortium of major Texas universities and health systems will participate, and the trial is intended to generate evidence needed to pursue FDA approval and make ibogaine treatments accessible through FDA-approved clinical trials, with patient safety and nonstate matching funds required by the grant structure.